| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -342,502 | -212,411 |
| Stock-based compensation | 69,304 | 46,602 |
| Depreciation and amortization | 2,896 | 1,884 |
| Deferred revenue | - | 984 |
| Noncash lease expense | 2,360 | - |
| Accounts payable and accrued expenses, compensation and related expenses | - | 11,160 |
| Accretion of purchase discounts and amortization of premiums on investment securities, net | 12,691 | 9,090 |
| Loss on disposal of property and equipment | -42 | -42 |
| Loss on equity method investment | 0 | 0 |
| Prepaid expenses and other assets | 18,531 | 11,325 |
| Accounts payable and accrued expenses, compensation and related expenses, and other liabilities | 17,807 | - |
| Noncash lease expense | - | 1,605 |
| Deferred revenue | -1,128 | - |
| Operating lease liabilities | -2,578 | -1,786 |
| Net cash used in operating activities | -285,021 | -174,303 |
| Purchases of investment securities | 790,781 | 574,081 |
| Proceeds from sales and maturities of investment securities | 912,886 | 530,514 |
| Purchases of property and equipment | 5,304 | 4,441 |
| Net cash provided by (used in) investing activities | 116,801 | -48,008 |
| Proceeds from issuance of common stock, net of commissions | 0 | 0 |
| Offering costs related to issuance of common stock | - | 0 |
| Proceeds from exercise of stock options and shares issued under employee stock purchase plan | 14,576 | 11,492 |
| Net cash provided by financing activities | 14,576 | 11,492 |
| Net change in cash, cash equivalents and restricted cash | -153,644 | -210,819 |
| Cash and cash equivalents at beginning of period | 265,845 | - |
| Cash and cash equivalents at end of period | 112,201 | - |
Crinetics Pharmaceuticals, Inc. (CRNX)
Crinetics Pharmaceuticals, Inc. (CRNX)